The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Advances Day 2019 | Single-cell multiomics to study malignant megakaryocytes
Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, discusses the future prospects of immunotherapy in myeloproliferative neoplams (MPNs), highlighting current research on novel targets that might selectively be expressed in the mutant clone of hematopoietic stem cells. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
